Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 66Active not recruiting 15Recruiting 10Terminated 7Unknown 4Withdrawn 3Not yet recruiting 1

Sponsor Class

OTHER 45INDUSTRY 18NIH 7NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1

Interventions

Cisplatin 14Radiotherapy 13Oxaliplatin 8Fluorouracil 7Gemcitabine 6Drug Therapy 6Leucovorin 5Doxorubicin 5Cytarabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5durvalumab 4Paclitaxel 4Etoposide 4Docetaxel 4Chemotherapy, Adjuvant 4Biological Therapy 4bicalutamide 3Rituximab 3Radiotherapy, Intensity-Modulated 3Polymerase Chain Reaction 3Platinum 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Gene Expression Profiling 3Dexamethasone 3Bortezomib 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × Dexamethasone × Clear all
NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡